PLUS THERAPEUTICS, INC. 8-K

What Happened

• Plus Therapeutics, Inc. announced on March 12, 2026 (Form 8-K) that it reported financial results for the fourth quarter and the year ended December 31, 2025. The company furnished a press release with those results as Exhibit 99.1 to the 8-K, which is incorporated by reference into the filing. The report was signed by President and CEO Marc H. Hedrick, M.D.

Key Details

• Filing date: March 12, 2026 (Form 8-K, Item 2.02 reporting results of operations and financial condition).
• Period reported: Fourth quarter and year ended December 31, 2025.
• Press release: Furnished as Exhibit 99.1 and incorporated by reference (dated March 12, 2026).
• Signature: Report signed by Marc H. Hedrick, M.D., President and Chief Executive Officer.

Why It Matters

• This 8-K formally notifies investors that Plus Therapeutics has released its quarterly and full-year earnings information; the press release will contain the detailed earnings, revenue, cash position, and any management commentary or guidance.
• Retail investors should review the furnished press release and any related investor materials or earnings call for the specific financial results and implications for the company’s outlook before making investment decisions.